title: Risk factors for developing apnea after immunization in the neonatal intensive care unit.
abstract: OBJECTIVE
  Among hospitalized NICU infants, preimmunization apnea is a well-recognized predictor of postimmunization apnea. However, predictors for postimmunization apnea among NICU infants without preimmunization apnea have not been investigated.
  
  
  METHODS
  Using a large NICU database in the Northern California Kaiser Permanente Medical Care Program, we abstracted NICU charts of infants who were hospitalized for > or = 53 days and who were also immunized, capturing preimmunization (24 hours before immunization) and postimmunization (48 hours after immunization) events. We assessed factors associated with postimmunization apnea by using multivariate logistic regression.
  
  
  RESULTS
  Of 16,146 infants admitted to the NICU, 557 received > or = 1 vaccine and 497 met the criteria for study entry. All infants with preimmunization apnea (n = 27) and all except 3 infants with postimmunization apnea (n = 65) had gestational ages of < 31 weeks. Multivariate analyses revealed preimmunization apnea as the most important predictor of postimmunization apnea, although higher 12-hour Score for Neonatal Acute Physiology II and age of < 67 days (mean cohort age) were also associated. Multivariate analysis exclusively among infants without preimmunization apnea similarly found elevated Score for Neonatal Acute Physiology II, age of < 67 days, and weight of < 2000 g to be associated with postimmunization apnea. Forty-nine infants without preimmunization apnea and with > or = 1 apnea predictor were discharged within 48 hours after immunization; 2 were subsequently readmitted because of apnea.
  
  
  CONCLUSIONS
  For infants in the NICU without apnea during the 24 hours immediately before immunization, younger age, smaller size, and more severe illness at birth are important predictors of postimmunization apnea.
authors.affiliation: Kaiser Permanente Vaccine Studies Center, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612, USA. nicola.klein@kp.org
authors.forename: Nicola P
authors.initials: NP
authors.lastname: Klein
authors.forename: Maria L
authors.initials: ML
authors.lastname: Massolo
authors.forename: John
authors.initials: J
authors.lastname: Greene
authors.forename: Cornelia L
authors.initials: CL
authors.lastname: Dekker
authors.forename: Steven
authors.initials: S
authors.lastname: Black
authors.forename: Gabriel J
authors.initials: GJ
authors.lastname: Escobar
mesh_terms: D001049:Apnea / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007114:Immunization / Q000009:adverse effects* / Q000379:methods; D015994:Incidence; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D014611:Vaccination / Q000009:adverse effects*; D022282:Vaccines, Acellular / Q000008:administration & dosage / Q000009:adverse effects; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D022282:Vaccines, Acellular; D017778:Vaccines, Combined